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Title: ‘Prevention is better than cure, but...’: Preventive medication as a risk to 
ordinariness? 
Abstract:  
Preventive health remains at the forefront of public health concerns; recent initiatives, 
such as the NHS health check, may lead to recommendations for medication in response 
to the identification of ‘at risk’ individuals. Little is known about lay views of preventive 
medication. This paper uses the case of aspirin as a prophylactic against heart disease to 
explore views among people invited to screening for a trial investigating the efficacy of 
such an approach. Qualitative interviews (N=46) and focus groups (N=5, participants 31) 
revealed dilemmas about preventive medication in the form of clashes between norms: 
first, in general terms, assumptions about the benefit of prevention were complicated by 
dislike of medication; second, the individual duty to engage in prevention was 
complicated by the need not to be over involved with one’s own health; third, the 
potential appeal of this alternative approach to health promotion was complicated by 
unease about the implications of encouraging irresponsible behaviour among others. 
Though respondents made different decisions about using the drug, they reported very 
similar ways of trying to resolve these conflicts, drawing upon concepts of necessity and 
legitimisation and the special ordinariness of the particular drug. 
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Title: ‘Prevention is better than cure, but...’: Preventive medication as a risk to 
ordinariness? 
Introduction 
Since the 1970s, health promotion campaigns targeting cardiovascular disease prevention 
have focused on behaviour change associated with ‘lifestyle’ factors such as diet, 
smoking and exercise, thus putting the emphasis on individual responsibility for heart 
health (Crawford 1977, Greco 1993, Lupton 1995). However, recent policy has increased 
the role of the primary care practitioner in this area, for example, through initiatives such 
as smoking cessation clinics (Department of Health (DH) 2002) and health checks (DH 
2009a). Indeed since the mid 1990s doctors have been encouraged to prescribe 
medication for people ‘at risk’ of heart disease, identified through opportunistic screening 
and risk assessment (DH 2000; Will 2005). Furthermore performance in reducing 
patients’ cardiovascular risk (in particular their blood pressure and cholesterol) was a key 
part of the Quality and Outcomes Framework under the GP contract (DH 2003), and 
systematic screening for cardiovascular risk was recently introduced in primary care in 
England and Scotland for all those over 40 (DH 2009a, Scottish Government 2009). 
These measures to reduce the risk of ‘at risk’ individuals will involve lifestyle advice, but 
also medication for cardiovascular risk reduction, such as statins, anti-hypertensives or 
aspirin (DH 2009b).  
In the current paper we focus on one type of preventive medication – aspirin – as a 
prophylactic for cardiovascular disease. Aspirin is widely available in the UK, as there 
are no restrictions on its sale as an everyday painkiller. It is commonly recommended for 
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secondary prevention following a myocardial infarction (Antithrombotic Trialists’ 
Collaboration 2002), but the last decade has seen much debate as to its efficacy in 
primary prevention, that is, for people who have not yet had symptoms of heart disease 
but may be at risk. A number of trials have been carried out to investigate this issue in 
different groups, and the media has followed developments , for example reporting on 
aspirin’s proposed benefits as a preventive measure (BBC 2005a, 2008) but also 
uncertainty in the medical profession (BBC 2005b, 2009). Interestingly daily aspirin has 
more recently been reported to reduce deaths from cancer (Rothwell et al. 2010). Such 
attention, along with the easy accessibility of the drug, means that it is likely that some 
people are self-medicating in a preventive manner, but little is known about this kind of 
use. 
In this paper we investigate responses to the idea of prophylactic aspirin among people 
invited to screening for cardiovascular risk and a subsequent trial of aspirin itself. We 
explore conceptualisations of the physical risks and benefits of the drug, along with 
broader understandings of appropriate action. We situate our data in the context of two 
broad fields of research: risk and responsibility in the prevention of heart disease, and lay 
views of medicine-taking.  
Risk and responsibility in the prevention of heart disease 
The concept of individual responsibility is central to discussions of heart health in the 
social science literature, and is evident in the complex interplay between professional 
attempts to define and reduce risk and lay understandings of disease and ageing (e.g. 
Nettleton 1996, Griffiths et al. 2006). The science of epidemiology emerged in the 20
th
 
5 
 
century as a powerful resource for states concerned to manage the social and economic 
burden of illness, by orienting action around the concept of risk and risky behaviours 
(Lupton 1995; Nettleton 1996).  Within a literature on ‘governmentality’, critiques of  
health promotion messages about changing this behaviour were associated with calls 
upon citizens to take responsibility for their health and accept the ‘duty to stay well’ 
(Greco 1993; Rose 1999). This paper contributes to the discussion of the ways in which 
lay people respond both to the communication of risk and the moral messages or ‘hidden 
scripts’ (Sachs 1996) which accompany it.  
Classic work exploring ‘lay epidemiology’ suggested lay people do make assumptions 
about the link between certain behaviours and heart disease, and attempt to judge 
‘coronary candidacy’ through comparisons to others, who were seen as having more or 
less risky lifestyles and/or physiology (Davison et al. 1989; 1991; 1992). Yet the 
candidacy construct also gave weight to factors such as fate or inheritance in attempting 
to assess one’s own risk, and paid attention to cases where unhealthy lifestyle did not lead 
to disease, or where people got ill despite leading apparently virtuous lives, countering 
any simple assumption of individual responsibility. 
The candidacy construct and its associated anomalies also appeared to modify decisions 
about engaging in preventive behaviour in complex ways:  such behaviour might be 
considered irrelevant in the context of the play of chance, or of inherited risk or resilience 
(Davison et al. 1992); conversely it could be seen as a way of ‘counter-acting the effects 
of heredity’ (Davison et al. 1989) for example through an increased effort to engage in a 
prophylactic lifestyle. More recently people with genetic conditions linked to increased 
risk of heart disease have been shown both to use inheritance to limit any assumption of 
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individual responsibility and to claim that a sense of inherited risk brings greater 
motivation for lifestyle change (Weiner 2009). This fits with a wider literature on the way 
in which genetic information is associated with new demands for prudence or 
responsibility (e.g. Hallowell, 1999; Novas and Rose, 2000). 
Finally, in discussions about lifestyle, a discourse of moderation has been presented as 
both responsible and reasonable (Backett 1992). Being too concerned with one’s health 
may have negative connotations in terms of how one may be judged by others (Cornwell 
1984). For example reporting the rarity of personal illness or visits to the doctor are ways 
in which one can help demonstrate and maintain one’s strength of character (Blaxter and 
Paterson 1982, Brown 2001). Thus leading a lifestyle that is sufficiently healthy, but not 
overly rigid would seem to be the most responsible and least risky choice. 
Lay views of medicine-taking 
Though sociological studies of medicine-taking originally focused on unpicking 
compliance, a wealth of qualitative studies has challenged the idea that ‘non-adherence’ 
with prescribed drug regimens should be conceived as the failure of individual patients to  
comply with professional advice (for example Adams et al. 1997). Rather, studies of lay 
meanings of medication repeatedly imply a deliberate decision to limit drug use – 
associated with framing medication as a disruption to ordinary life or routines and as both 
physically and morally risky, for example in fears about dependency (Britten 1994, 
Pound et al. 2005). Such fears may pose a challenge to the acceptability of prophylactic 
medication, as they appear intensified in conditions requiring long term use (Hansen and 
Hansen 2006, Nørreslet et al. 2010). 
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Widespread resistance to medicine (Pound et al. 2005) associated with physical riskiness 
also manifests in concern about side effects; the severity of these is weighed up against 
the symptoms or inconvenience of the condition (e.g. Benson and Britten 2002, Hansen 
and Hansen 2006). Yet with prophylactic medicine use – and in the absence of an 
immediate impact on a person’s life – it is likely to be less clear what physical benefits, 
present or future, may be attributed to the drug and thus balanced against these risks 
(Pound et al. 2005). Furthermore, willingness to take medication relates to acceptance of 
and identification with a condition (for example Britten 1994, Adams et al. 1997). 
Without an embodied experience of illness, identification with risk appears likely to be an 
important part of any decision to start or continue such medication. In addition, actively 
taking medication could imply over involvement with one’s health, and thus pose a moral 
risk. Non-prescription preparations appear to be subject to the same norms of responsible 
use as prescription drugs (Lumme-Sandt et al. 2000, Moen et al. 2009). Indeed 
demonstrating a preference for minimal medication use could be more important in the 
case of OTC drugs, as this is where consumers have most choice – and so the opportunity 
to choose responsibly (Lumme-Sandt and Virtanen 2002, Hansen et al. 2009).  
It is important to note therefore that as with talk about other health behaviours, people’s 
accounts about medication use are suffused with the moral work they may be doing to 
construct themselves as responsible. Mills (1940) suggested this was because talk about 
future action employed ‘vocabularies of motive’ which are most typically used to explain 
behaviour that may be viewed as irresponsible, such as not breastfeeding (Murphy 2004). 
When the behaviour under discussion is less ‘untoward’, the onus may be on presenting 
oneself as ordinary, for example by returning to everyday domestic tasks and routines - 
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an accessible way of appearing responsible (Radley and Billig 1996). Nevertheless, such 
work has an important effect for qualitative studies investigating health beliefs, including 
medicine-taking; people may unwittingly emphasise examples of their own responsible 
behaviour in the interview situation, countering any ‘suggestion of weakness’ or threat to 
‘ordinariness’ that comes with unquestioning acceptance of medical treatment (Radley 
and Billig 1996). 
As shown, the concepts of both responsibility and risk run through the two sets of 
literature discussed, but in very different configurations. While beliefs about individual 
responsibility for cardiovascular risk may be complex, as demonstrated by the coronary 
candidacy construct, taking individual action to reduce the risks appears desirable. 
Uncertainty remains however about how people will respond to the offer of prophylactic 
medication following communication of their individual risk, but in the absence of a 
formal diagnosis. In medicine taking, responsible behaviour is often presented as a matter 
of avoiding drugs. This may reduce the acceptability of preventive medication, which 
needs to be used for many years in the absence of both specific symptoms and a clear 
condition with which people may identify. Thus prophylactic medication presents 
particular difficulties for lay reasoning. Before exploring this further through the specific 
example of aspirin, we explain the origins of the data.  
 
Methods 
Participants were sampled from a healthy population aged 50-75 invited to participate in 
the Aspirin for Asymptomatic Atherosclerosis (AAA) trial.
i  
The trial set out to identify 
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people with asymptomatic atherosclerosis among otherwise healthy individuals using the 
ankle brachial pressure index (ABPI) and to assess the efficacy of aspirin in preventing 
cardiovascular events in those identified (Fowkes et al. 2010). A low ABPI (≤0.95) is 
associated with an increased risk of mortality, coronary artery disease and stroke, and is 
proposed to be a better predictor of disease than conventional risk factors (smoking, 
hypertension, and hypercholesterolemia) (Heald et al. 2006). Following screening 3350 
eligible individuals with screen-detected atherosclerosis were randomised to receive 
either aspirin (100mg daily) or placebo for 5 years. In 2010, the trial reported that aspirin 
did not significantly reduce vascular events in this particular group (Fowkes et al. 2010), 
concurring with a meta-analysis published shortly beforehand which found aspirin to 
have only a limited effect for healthy individuals (Antithrombotic Trialists’ Collaboration 
2009). However, at the time of the qualitative sub-study reported here – while the AAA 
trial was in progress - there was no good evidence on this question.  
Our qualitative research involved 77 individuals with different relationships to the trial: 
trial participants; participants who had stopped the trial medication; eligible individuals 
who declined to participate in the trial; individuals whose screening result made them 
ineligible for the trial; and individuals who did not attend the initial screening for the 
trial. Table 1 provides a full description of each of these groups, with numbers per group 
and recruitment methods. 
[Table 1 about here] 
Ethical approval was granted by Greater Glasgow (Community/Primary Care), 
Lanarkshire, and Lothian Local Research Ethics Committees. Potential respondents were 
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offered the choice, where feasible, of participating in either an individual interview or 
focus group. HE conducted the interviews and moderated the focus groups (with an 
assistant moderator). With written consent all were audio recorded, transcribed verbatim 
and anonymised.  
A semi-structured topic guide was used covering three main areas: screening for 
cardiovascular risk, preventive medicine (focusing on aspirin), and trial participation. HE 
conducted the initial analysis which was inductive and interpretative, informed by the 
constant comparative method (Strauss and Corbin 1990, Charmaz 2006). Fieldwork was 
undertaken in three waves, with preliminary analysis informing subsequent waves: 
transcripts were read and re-read, emerging themes were noted and preliminary codes 
developed and the coding framework refined throughout. Coding was facilitated with 
NVivo (qualitative data indexing software). This paper draws upon data generated when 
respondents were asked their views on cardiovascular prevention and aspirin specifically.  
 
Findings 
Qualitative study respondents were between 52 and 77 years old (mean = 63.7, standard 
deviation = 7.3). Forty-six were female, all were of ‘White British’ ethnicity, and there 
was a wide range in socioeconomic background: the median Carstairs deprivation index 
was 3, and the sample included individuals from all seven levels. 
ii
  
 
Clashing of norms 
The data raised three key clashes of norms. We first present two clashes that arose in 
relation to the use of preventive medication at the individual level. Respondents’ 
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accounts indicated an almost unanimously positive view of prevention. Reference to the 
adage ‘prevention is better than cure’ was common – both when talking about prevention 
in generic terms or specifically in relation to aspirin:  
‘I think everybody should take a preventive thing. Better to prevent it than try and 
cure it.’ (R2.11, stopped trial medication, now on prescribed aspirin) 
 ‘Well prevention’s better than cure…if you find out you’ve got the lower count 
[‘at risk’ result] in your ankles and you’re told to take [aspirin] and you don’t take 
it then more fool you.’ (R4.2, ineligible for trial)  
Two norms are thus apparent concerning prevention: first, that prevention of disease can 
only be a good thing. Second, that engaging in prevention is responsible and one’s duty, 
as demonstrated by the language used (for example ‘should’ and ‘fool’).  
Despite these assertions, but unsurprisingly given previous literature, a dislike of taking 
pills in general was highly salient in respondents’ accounts, including those of trial 
participants. This dislike related to avoidance of ‘chemicals’, concern about side-effects 
and fear of dependency, for example: 
‘If you’re taking a lot, it knocks the hell out your stomach […] Given the choice, 
I’d rather not take medication full stop.’ (R2.6, participant who stopped 
medication). 
‘I don’t want to be taking tablets if I can avoid it [...] I don’t want to be dependent 
upon medication.’ (R2.4, participant who stopped medication). 
Some respondents described a degree of pride in ignorance about drugs and having 
avoided taking them:  
‘I’m not in the habit of taking any kind of tablets you know I couldn’t tell you the 
difference between them, a disprin and an aspirin […] If I’ve went through 60 
years of my life without taking anything like that, I’m just gonna leave it, not take 
it.’ (R2.2, participant who stopped medication) 
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Furthermore the desire to be seen as someone not needing medication sometimes involved 
distancing oneself from the type of person who takes too many drugs. Such implications 
were not limited to respondents who took no medication; for example the following trial 
participant distanced her acceptance of the trial drug from others’ excessive medicine use. 
‘I’m not a pill popper, like some people with their six bottles.’ (R1.3, trial 
participant).  
Thus, two norms about medication were evident: a general dislike of taking pills, and 
concern about moral implications of being seen as a ‘pill popper’. These norms came into 
conflict with shared beliefs about preventing cardiovascular disease. The desire to resist 
medication clashed with a sense that preventing something must be preferable to having 
to deal with the consequences later, while to need to avoid being seen as a ‘pill popper’ 
potentially clashed with the need to be seen to engage actively with prevention.  
A third clash – related to implications at the population level - emerged from when 
respondents were specifically asked about the idea of using aspirin as a preventive 
medication. In terms of benefits at this level, some respondents could see the appeal of 
promoting a drug such as aspirin for prophylactic means, particularly to target people 
who appeared unable to engage in a preventive lifestyle.  
‘I know that a lot of people will benefit from that, for the simple reason that they 
can pop an aspirin […] they do that and still continue to have fish and chips […] . 
So that type of person, it’s wonderful for.’ (R3.9, declined trial - not on 
medication). 
Indeed it could be argued that if people were not changing their behaviour, taking a pill 
might be responsible action given the over-riding concern with prevention. One 
respondent made this argument with reference to the failure of health promotion 
campaigns: 
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‘The fact of the matter is, they’re not having success changing people’s lifestyles 
yet, well not seriously, so if you say, “well if you do continue to smoke and drink 
and do all the things that are bad for you, then at least take this aspirin, it’ll help a 
bit.”’ (R1.4 trial participant) 
Furthermore, the idea that preventive medicine could in fact limit the damage done by 
lifestyle was reinforced by stories of known others for whom aspirin may have 
counteracted unhealthy behaviours:  
‘My wife’s mother, she had heart problems as well and she always took an aspirin 
and it kept her going for years despite her smoking.’ (R2.7 participant who 
stopped trial medication). 
However, respondents more typically described the type of person who would benefit 
from preventive medicine in a way that emphasised their own distinction from that type 
in terms of lifestyle, for example: 
‘So that type of person, it’s wonderful for. I’m quite happy to deny myself the fish 
and chips, the meat, and things, and discipline myself to what I think is necessary. 
[…] The majority of people, 7 out of 10 people are quite happy to go along, take 4 
or 5 medicinal things from the doctor, instead of an alternate lifestyle and food.’ 
(R3.9, declined trial - not on medication). 
 
Although the potential benefit of preventive medication was raised by some respondents, 
concern about potential negative implications was more common and raised a great deal 
of unease. First, there was wariness about the drug being promoted as a ‘quick fix’ – an 
intervention that could remove the need to manage risk responsibly on an ongoing basis, 
i.e. by balancing out unhealthy behaviour. This was primarily presented through 
assertions that people should not expect miracles, without making some effort to change 
their lifestyle: 
‘They might think it was a panacea for everything.’ (R3.4 declined trial - not on 
medication) 
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There was a general feeling that encouraging preventive medication in the context of 
unhealthy behaviours was not only rewarding irresponsibility, but conveying a 
misleading message and ‘false sense of security’. Thus many respondents insisted that 
lifestyle change should accompany preventive medication use. For example: 
‘Without sounding like some kind of new-age person, at the same time it’s 
important to stress the holistic approach [...] - absolutely fine to use the chemical 
remedy - but you try and use the personal lifestyle approach to things as well.’ 
(R4.5 ineligible for trial) 
Alongside this concern, respondents also appeared bemused at the idea, or considered it 
unbelievable: 
FG1B.3: ‘It seems much easier if all you have to do is pop a pill… You turn to the 
newspaper headlines, somebody picks up the Daily Mail and says, “Ooh, I’ll take 
an aspirin and I’ll be all right. I’ll just go and have six pints tonight and then take 
this afterwards and I’ll be fine.”’ 
FG1B.5: ‘That’s what I mean, it’s a daft idea.’  
(Trial participants) 
 
The perspective of someone who was engaging in such an approach came from the 
following respondent who was self-medicating with aspirin: 
‘I take the aspirin really because I can’t stop smoking, […] I don’t take the aspirin 
so I can go on smoking, I take the aspirin because I smoke and I hope that it might 
reduce the chances…of a heart attack. But in my own mind I probably realise that 
smoking does so much damage it probably won’t help, but it’s worth a try.’ 
(R3.10 declined trial - self-medicating with aspirin) 
So even this respondent’s account of her behaviour was accompanied by a statement that 
the two types of action were distinct; aspirin did not make smoking possible, rather it was 
a responsible choice while she had not managed to quit, but even then it could not be 
relied upon.  
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Thus the third clash of norms raised by the idea of preventive medication operated at the 
population level between a potentially appealing approach to health promotion and the 
danger of encouraging irresponsible living.   
To summarise, the idea of preventive medication raised three clashes of norms. To the 
extent that respondents sought to resolve these conflicts, how did they present the 
solutions?  
 
Resolution 1: Necessity and legitimised medicine taking 
When discussing the decision to take or reject prophylactic aspirin, the language of 
‘necessity’ served to cut through respondents’ deliberations and present medicine taking 
as responsible in particular circumstances. This was apparent even for respondents who 
expressed a preference for avoiding medication, for example: 
‘Nobody likes taking pills but if you’ve got to, you’ve got to.’ (R2.9 participant 
who stopped trial medication – now on prescribed aspirin)   
So what would it take to convince respondents that drug taking was necessary for the 
individual? Despite many respondents mentioning factors that enhanced their coronary 
candidacy, in particular talk of family history and heredity, it was more usual for such 
factors to have influenced attendance for screening than be used to account for actually 
taking preventive drugs. When talking about the decision to take drugs, respondents 
tended to refer to other kinds of legitimisation, particularly advice from doctors. Indeed 
this was captured in one respondent’s almost rhetorical question to her fellow focus 
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group participants: ‘We’ve read about the supposed benefits, but have any of us here 
actually decided, well off my own back I’ll take an aspirin?’ (Focus Group 2) 
Legitimisation emerged as possible via various routes but usually seemed to involve a 
healthcare professional. Given the context of the current data (the AAA trial), a common 
route was via the ABPI screening, and receipt of an ‘at risk’ test result. While the initial 
result was typically given by a research nurse, it was not unusual for respondents to 
report having discussed it with their general practitioner (GP): 
‘I went to my own doctor…I spoke to him and told him what was happening [the 
ABPI result] and he said, “do you want to go on aspirin?” and I said, “well it 
sounds like I might have to, I’d sooner be on it than nothing.”’ (R3.8 declined 
trial, on prescribed aspirin). 
However GPs could also veto the idea of taking preventive medication in response to this 
measure of risk. For example one respondent reported that his GP had “pooh-poohed” the 
idea. 
The legitimising roles attributed to the GP varied. While the respondent above described 
initiating a conversation, a couple of respondents insisted that they would leave the 
decision to their GP altogether, while others talked in terms of getting permission from 
the doctor for a decision taken outside the consultation:  
‘I just go with what the doctor puts me on really… if he said “I wanna put you on 
aspirin,” I would probably say, “we’ll try it”...’ (R3.1 declined trial) 
R1.6 (trial participant): ‘Well yes I would take it by myself but they say you’ve 
gotta get the doctor to get permission first. […] I would need to find out if I 
needed it and I would take it then […].’ 
R1.6’s wife: ‘My sister and her man take half an aspirin each…’ 
R1.6: ‘But did they ask for permission from the doctor?’ 
R1.6’s wife: ‘I never asked them.’ 
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In the second quote the respondent moves between the idea of seeking permission for his 
preferred course of action and ‘need’ as something identified by the doctor. In returning 
to the theme of permission in relation to his wife’s relatives however, he reveals that this 
kind of legitimisation does not appear to be a more general topic of conversation.  
A couple of respondents talked less in terms of seeking permission than checking with 
the GP for safety – for example establishing whether aspirin would interact with any 
other medication. Unusually, the respondent quoted earlier who was self-medicating 
following her ABPI result, had not felt the need to inform her GP, although when the 
topic arose in the interview she suggested that she had considered checking whether one 
type of aspirin was preferable: 
‘I buy them in Superdrug, and I just take one dissolved in water, most 
days…maybe 5 times a week. (You haven’t told your GP or anything?) No I 
haven’t been to see the GP for quite a long time […] I keep thinking about it and 
saying maybe I should go along and see him ‘cause maybe I should be taking 
[sugar-]coateds if I’m going to take them as regular as that.’ (R3.10 declined trial 
- now self-medicating with aspirin) 
A special role seemed to be given to clinicians to weigh up the risks and benefits of 
aspirin and pronounce it ‘necessary’.  Again responsibility ran through these discussions. 
The emphasis on legitimisation shifted responsibility for the decision to the health care 
professionals, and having one’s medication prescribed/approved in this way then lent 
legitimacy to the user, whose behaviour became responsible not only in taking the drug 
but also investigating the case for taking it appropriately. 
 
Resolution 2: The special ordinariness of aspirin 
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Aspirin was repeatedly claimed as known and trusted by respondents including those who 
declined the trial or had stopped taking the trial tablet. Factors that seemed to contribute 
to the feeling of knowing the drug included: the length of time that it had been around for 
general use; reference to its use by family members in the past; and personal experience: 
‘Aspirin’s been on the go for many, many years, it was used for most things 
before all the modern drugs.’ (FG1A.9, trial participant)  
‘My mother always had an aspirin you know every day…for years and years […] 
it was just something that she seemed to know was good for her.’ (R1.3, trial 
participant) 
‘[My doctor] gave me other tablets which I don’t take […] I just take the high 
blood pressure [pills] and the aspirin. I know the aspirin - I think that does do you 
good.’ (R5.5, screening non-attender, on prescribed aspirin) 
‘Knowing’ the drug and believing that it ‘does you good’ gave aspirin a special status. 
Awareness of contemporaries who were taking it demonstrated its ordinariness and 
validated respondents’ own confidence in it:  
‘I’ve spoken to other chaps about my age and there’s a few that are on it and 
…I’m quite happy to be on it, I feel very confident about it, it’s a strange thing 
but I feel it’s a real help the aspirin because it’s had such good reports.’ (R5.4, 
screening non-attender, on prescribed aspirin) 
Such awareness of aspirin’s known benefits and widespread use seemed to blur the 
distinction between a level of risk at which it was known to help (for example in 
secondary prevention) and those for which efficacy was still being weighed against harm. 
In our sample, this led to acceptance of efficacy in primary prevention despite its use in 
these circumstances still being unknown at this point, and a question for the AAA trial. 
 ‘I thought aspirin had been a proven blood thinner and so was accepted as such, 
and most people, once they’ve had stroke, heart attack, anything like that without 
complications in the digestive system are given a daily aspirin at this moment.’ 
(FG2.3, participant who stopped medication) 
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Many respondents were happy to accept the drug as ‘safe’, and again this seemed to be 
associated with its known and trusted status. Susceptibility to adverse side effects from 
aspirin was also discussed in these terms – there was a general opinion that an individual 
would know by this stage in their life if they were particularly sensitive to aspirin or 
likely to have side effects. For example: 
‘A friend of mine, she was asked to [participate in the trial] and her son-in-law 
who’s a doctor advised her against it because she’s had stomach ulcers and 
whatnot and he said, no it’s too risky to take […] (Were you worried about any 
side effects?) No, no well this person, she’d had stomach trouble years and years 
before […] but it didn’t worry me at all.’ (R2.5 participant who stopped trial 
medication – now on prescribed warfarin) 
Respondents’ accounts indicated that knowing aspirin and awareness of likely 
manifestation of side effects, made balancing the risks and benefits easier perhaps than 
for other drugs:  
‘I get tummy trouble, so I try to avoid aspirin if I can, I don’t take aspirin, I’m 
lucky if I have a couple of tablets a year and I didn’t really fancy going on a 
prolonged sort of dose of it.’ (R3.1 declined to participate in trial to avoid aspirin) 
But most respondents – who did not feel this susceptibility – balanced knowledge of side 
effects against the dangers of heart disease: 
‘…[aspirin] can cause ulcers… of the stomach, and there’s a little niggle, when I 
was getting this indigestion, I’ve got to admit I thought about that, …but there 
again I think there’s a risk with all tablets. […] if I had an ulcer, they could sort of 
do something about that, but if I had a heart attack, there would be no point, I 
probably wouldn’t be here, you know, you’ve got to weigh the pros and cons.’ 
(R1.5 trial participant) 
To summarise this section, aspirin emerged as a known and trusted drug; awareness of its 
longstanding and widespread use helped establish its ordinariness, thus furthering its 
acceptability. Such ordinariness and acceptability was sufficient in making the taking of 
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aspirin a responsible choice, and provided a second way of dealing with the clashes of 
norms described in our first section. 
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Discussion 
This paper has introduced data about preventive medication, with a particular focus on 
aspirin. The idea of taking preventive medication raised dilemmas in the form of three 
conflicts or sites of tension. First believing that prevention could only be a good thing 
was complicated by the desire to avoid medication whenever possible. Second the duty to 
engage in prevention was complicated by the need not to be seen as a ‘pill popper’. 
Finally, at the population level, the potential appeal of preventive medication as an 
alternative approach to health promotion was complicated by unease about the 
implications of encouraging irresponsible behaviour. A sense of dissonance was evident 
not only in respondents’ accounts of their beliefs about prevention and about medication, 
but also in the observation that some respondents’ behaviour appeared to be at odds with 
some of their stated beliefs about medicine use. Yet respondents’ accounts typically 
resolved such dissonance with reference to two main themes: first the language of 
‘necessity’ to describe circumstances where medicine-taking was considered a 
responsible choice; and second, in this particular case of aspirin, discussions of the drug’s 
familiarity due its widespread and longstanding use helped make it appear both special 
(among other drugs) and ordinary. 
As with many qualitative studies of health and illness, our data is limited to respondents’ 
accounts of their actions and was potentially influenced by the methods of data gathering 
(as Radley and Billig 1996) and complicated by respondents’ desire to present themselves 
in a responsible light (Mills 1940). Furthermore, given that respondents were recruited 
because of their particular relationship to the trial (current trial participant, ex-trial 
participant who had stopped medication, eligible individual who had declined trial, and 
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so on) they may have felt the need to justify the decision they had made about the trial in 
discussion of their use of aspirin. Despite this, we found very similar themes in the data 
from all groups in relation to the clashes of norms raised by preventive medicine, and the 
emergent ‘solutions’. 
The positive views expressed about prevention may reflect the consolidation of the risk 
paradigm in healthcare over the past two decades and the penetration of government 
messages about healthy living (e.g. Lupton 1995, Nettleton 1996, Griffiths et al. 2006); 
yet the desire to appear to take prevention seriously sat awkwardly with a well-
documented resistance to medication taking (Britten 1994, Pound et al. 2005). The ways 
in which our data reflect moral work – in which respondents present themselves as 
actively seeking health and managing the need to be seen to avoid medication where 
possible – are perhaps not surprising given previous literature (Radley and Billig 1996, 
Lumme-Sandt et al. 2000). However, the tension between different norms appears 
intensified in the novel situation that preventive medication creates making it less 
obvious what the responsible choice should be in comparison to more straightforward 
examples such as taking medicine for an established condition or following a healthy 
lifestyle ‘to stay well’ (Greco 1993).  In addition, discussions of the preventive use of 
aspirin went beyond the dilemmas raised at the individual level, which we had not 
anticipated. Respondents repeatedly emphasised that the best route to prevention was 
lifestyle change, and barriers to lifestyle change or causes of heart disease relating to the 
social or physical environment (for example Davison et al. 1992, Sachs 1996) were 
overshadowed by concern about the ‘moral hazard’ represented by the offer of a 
preventive drug. Perhaps the greatest amount of moral work done by the respondents was 
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in relation to the individual level, and the idea (actual or hypothetical) of taking the drug 
themselves, but discussing the moral quandary at the societal level provided an easy way 
for respondents to demonstrate their own responsibility by distinguishing themselves 
from the type of person to whom preventive aspirin may appeal.  
Respondents also made frequent use of the theme of ‘necessity’ to resolve some of the 
clashes raised by the offer of prophylactic medication. While this concept has emerged as 
important in previous studies of medicine taking (Moen et al. 2009, Hansen et al. 2009), 
it was particularly useful here; in our data uncertainty about risk and the asymptomatic 
nature of the risk factor (atherosclerosis) meant that consideration of personal risk factors 
was not sufficient alone, instead certification of legitimacy was used to justify medication 
taking. Legitimacy in the form of professional sanctioning allowed respondents to 
mitigate any admission of willingness to take drugs long term, and distinguish this 
behaviour from unnecessary medicine taking. Such authorised medicine-taking echoes 
previous literature; the importance of a doctor’s opinion in patients’ decisions about 
drugs has emerged in relation to both prescribed drugs such as hypertensives (see Benson 
and Britten 2002; Moen et al. 2009) and OTC medication (Lumme-Sandt and Virtanen 
2002), though we noted that it might not be a topic for conversation outside the research 
interview.  
Less predictably, aspirin’s longstanding presence in the home medicine cabinet, along 
with awareness of old wives’ tales and contemporary recommendations for its use 
contributed to respondents knowing and trusting the drug, and gave it a special status. 
Discussion of this factor appeared to offer another way out of the dilemma caused by the 
clash of norms. As we might expect, there was some calculative talk about the risks of 
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side effects (Benson and Britten 2002, Hansen and Hansen 2006), but respondents’ 
awareness of the gastro-intestinal risks of aspirin use was minimised by the expectation 
that adverse reactions would be treatable, most likely limited to people with previous, 
probably known, susceptibility, and minor compared to the possible benefits in protection 
against heart disease. In our conceptualisation of aspirin’s status we draw upon Radley 
and Billig’s (1996) concept of special ordinariness. For them the concept referred to the 
moral work done (typically by interviewees) in countering the stigma of illness by 
reference to involvement in relatively mundane household work. Here we argue that our 
respondents’ talk about the ‘ordinariness’ of aspirin allowed them to counter negative 
images of the pill popper, and present themselves as responsible medicine users.  
A further finding from our study related to the use of ‘others’ whose behaviour could be 
presented as untoward or reasonable, as respondents sought to present their own choices 
as responsible. This kind of reasoning emerged in two distinct forms in our data. Just as 
‘lay epidemiology’ worked through observation of other people’s coronary candidacy 
(Davison et al. 1989, 1991, 1992), our respondents invoked a vague category of ‘other 
people’ to distance themselves from an illegitimate trade off between lifestyle change and 
the apparently easy option of medicine use. In this case the ‘other people’ were not used 
to sanction unhealthy behaviour but to underline the importance of taking responsibility 
for staying well.  However we also noted that respondents referred to specific known 
others such as contemporaries who took aspirin to emphasise its safety and effectiveness. 
Though discussion of other people’s behaviour has not been a strong theme in previous 
work on decisions about medicine use, here we suggest such talk helped present aspirin 
and aspirin-taking as an ordinary and acceptable means of managing risk.     
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Implications and conclusions 
Since this study was carried out, the trial in which it was embedded has reported that the 
benefits with regards to preventing cardiovascular events do not outweigh the risks of 
aspirin in this particular group – otherwise healthy individuals with screen-detected 
atherosclerosis (Fowkes et al. 2010). We do not know how far the attractions of aspirin 
reported here will change in the light of dissemination of the AAA trial results. However, 
research on the clinical effects of aspirin continues and the recent report that aspirin helps 
to prevent deaths from cancer received significant coverage by the UK media (for 
example, Bosely 2010) may work to confirm some lay people’s beliefs about its value in 
risk reduction or promoting health in general. The extent to which aspirin is given special 
status in lay accounts may be of concern to healthcare professionals who remain wary of 
the physical risks demonstrated in the AAA trial and other studies. Building on our 
analysis, more work might be done on beliefs about other established primary prevention 
drugs like statins and anti-hypertensives, which although not having quite the 
longstanding status of aspirin, are nevertheless gaining in familiarity. Healthcare 
professionals and those invested in public health may also take comfort from our 
respondents’ dislike of the idea of ‘trading off’ by substituting medication for lifestyle 
change. Yet to the extent that policy makers and practitioners continue to promote the use 
of some prophylactic medicine in response to risk, they may also wish to reflect on the 
apparent emphasis given to advice from a general practitioner in deciding that a drug was 
‘necessary’ and overcoming resistance to medication. From a theoretical perspective, this 
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finding suggested both limits to the acceptance of individual responsibility for prevention 
and the continued influence of professional views in this area. 
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Table 1: Qualitative study participants: description of the different types of participant including recruitment details.  
Group name 
 
Description of group (in 
terms of relationship to the 
trial) 
N 
 
Recruitment details 
‘Trial 
participants’ 
Attended screening, eligible 
to participate, recruited to 
trial, taking trial tablet and 
attending annual clinic 
visit. 
Int:9 
FG:9+7 
 
All trial participants attending annual clinic visit during a 3-week 
period were given invitation letter and PIL by research nurse.  
Contact details of interested individuals passed to [Author1], who 
telephoned to check willingness to participate. 
‘Stopped trial 
medication’ 
Attended screening, eligible 
to participate, recruited to 
trial, but had stopped trial 
tablet, and receiving phone 
follow-up. 
Int:11 
FG:6 
 
All individuals receiving annual follow-up phone call from trial 
nurse during a 1-month period were informed about the study.  
Contact details of interested individuals passed to [Author1], who 
telephoned to check willingness to participate. 
‘Trial decliners’ Attended screening, eligible 
but declined to participate 
in trial. 
Int:11 All individuals who declined to participate in the trial during a 3-
month period were sent invitation letter, PIL and opt-in reply slip.  
[Author1] telephoned individuals who returned reply slip to check 
willingness to participate 
‘Ineligible for 
trial’ 
Attended screening, but 
ineligible for trial due to 
low risk from diagnostic 
test (ABPI >0.95). 
Int:9 
FG:3+6 
   
All individuals attending screening but ineligible for trial during a 
3-week period were given invitation letter and PIL.  
Contact details of interested individuals passed to [Author1], who 
telephoned to check willingness to participate. 
‘Non attendees’ Did not attend screening Int:6 All individuals invited to screening during a 2-week period who did 
not attend, were sent invitation letter, PIL and opt-in reply slip by 
post. 
[Author1] telephoned individuals who returned the reply slip to 
check willingness to participate 
Key to abbreviations in Table 1:  
Int: Individual interview  
FG: Focus groups 
PIL: Participant Information Leaflet 
